MSB held the EVERGLOW event at the M-First Lounge in its Head Office transaction branch to thank female Priority customers in the M-First segment on Vietnamese Women's Day, 20/10. The program featured 1:1 health consultations with the Hong Ngoc Medical System, talks by Phạm Thị Thùy Dương, director of the IVF centre, on health care, and by beauty expert Nguyễn Ngọc Nữ on skincare, along with hands-on activities such as a perfume-making workshop. MSB says the event is part of expanding its M-First privilege ecosystem, linking financial services with quality of life. A related health care program with Hong Ngoc runs from 01/10/2026 to 09/09/2027, offering check-up, screening and VIP benefits, with some benefits extended to members' family members.
Summary written by Upside AI from the original article. Read the source for full details.
Original headline: MSB mang trải nghiệm EVERGLOW đến khách hàng nữ M-First
Keywords
Open a keyword to see other news on the same topic.
Related tickers and likely impact
MSB
• NeutralMSB Bank
Relevance: low
| Market | Vietnam stocks |
|---|---|
| Exchange | HOSE |
| Sector | Banks |
| Market cap | 55,411 bn VND |
| P/E | 9.4 |
| P/B | 1.22 |
| Close on 10/19/2026 | 14.80 |
| Change that session | 0.00% |
Impact is scored by AI from the headline and may be wrong. It is not investment advice.
Related news
- Is UnitedHealth Group Stock a Buy After Another Solid Quarter?
UnitedHealth beat expectations in Q3, with revenue of $112.7 billion (versus $113.2 billion a year earlier and $111.4 billion expected) and adjusted EPS of $4.69 against Wall Street's $4.14 estimate. The company raised its full-year adjusted EPS guidance to at least $20.50, from the previous $19.50 to $20, helped by exiting unprofitable markets and investing in AI. The stock closed just over $401 last week and is up around 22% in 2026, though its five-year returns remain negative. The article says the forward P/E of around 16 is below the more than 19 times that the average S&P 500 stock trades at, and the 2.3% dividend yield adds appeal for income investors. It concludes UnitedHealth remains a worthwhile option given its modest valuation and improving earnings.
- Warren Buffett's Bluntest Warning Yet -- and 3 Stocks Built to Survive It
Warren Buffett, now chairman emeritus of Berkshire Hathaway, warned at the May shareholder meeting that 'we've never had people in a more gambling mood than now,' pointing to individuals rushing into short-term options and market bets. The article argues the S&P 500 and quality stocks have historically recovered from turmoil, and that pharma and biotech firms can hold up in tough times because patients always need treatment. It highlights three picks: Vertex Pharmaceuticals (VRTX), the cystic fibrosis leader that recently purchased Crinetics; Eli Lilly (LLY), whose tirzepatide brought in more than $14 billion of its $23 billion revenue in the recent quarter; and AbbVie (ABBV), where Rinvoq and Skyrizi each grew 24% and which is a Dividend King with more than 50 consecutive years of dividend increases.
- Stocktwits Pharma Pulse: Moderna-Merck Cancer Vaccine Grabs Spotlight As Kidney-Cancer And MS Data Pour In
Biotech news this week focuses on kidney cancer, multiple sclerosis, Huntington's disease and personalized cancer treatment, as Arcus Biosciences (RCUS), Alnylam (ALNY), Moderna (MRNA) and Merck (MRK) release clinical updates alongside earnings and conferences. Last week, the health care ETF XLV gained 3%, outperforming SPY (down 2%) and QQQ (down 6%), while the biotech ETF XBI fell 6%. Arcus will present kidney-cancer data from its ARC-20 study of Casdatifan, Achieve Life Sciences will report year-long Cytisinicline findings for smoking cessation after a June FDA rejection it says concerned manufacturing and labeling, and Alnylam will share initial Phase 1 ALN-HTT02 results for Huntington's disease. Moderna and Merck will present Phase 3 INTerpath-001 melanoma data on Saturday, comparing individualized treatment intismeran autogene plus Keytruda with Keytruda alone after surgery, while a number of other companies will present multiple sclerosis updates through the week.
- Where Will CRISPR Therapeutics Stock Be in 2030?
Shares of CRISPR Therapeutics have fallen about 47% since mid-October 2021, while the S&P 500 has gained almost 73% as of writing, despite clinical and regulatory progress over the past five years. Casgevy, developed with Vertex Pharmaceuticals, was approved in 2023 and early 2024 for transfusion-dependent beta-thalassemia and sickle cell disease, making it the company's first commercial product and the first approved CRISPR-based gene-editing therapy. Other candidates include CTX310, aimed at lowering LDL cholesterol and triglycerides, where Phase 1 data showed significant decreases in both; zugo-cel for autoimmune diseases and blood cancers; and CTX611, an anticoagulant that could be given twice a year. Casgevy's label now covers patients as young as two, adding about 5,500 U.S. patients at $2.2 million per treatment course. The article warns of possible clinical failures and the costly, one-time nature of many gene-editing therapies, which makes profitability uncertain.
- ELDER: The childish lies of Medicare for all
Larry Elder argues that the Washington Post Editorial Board has repeatedly exposed Medicare for All promises by Democrats, including Michigan Senate candidate Abdul El-Sayed, as flat-out lies. He cites Post editorials on Britain's National Health Service, where 6.24 million patients were waiting for treatment in England as of October, and on California, where single-payer was estimated to cost $494 billion to $552 billion a year, compared with a proposed state budget of $349.4 billion. The column notes that roughly three-quarters of Medicare for All supporters believe billionaires could pay for it, but only 40% knew it would require raising taxes on most taxpayers. Elder says politicians make similar claims about green energy, expanded Social Security, free college and government-run childcare.
- Medicare open enrollment : Why premiums could increase for some enrollees
Medicare open enrollment runs until Dec. 7 for plans effective Jan. 1, and several changes could raise costs. The Part D out-of-pocket cap rises to $2,400 from $2,100 in 2026, the standard deductible rises from $615 to $700, and the Trump administration is ending a temporary Part D premium subsidy. KFF estimates that AARP Part D enrollees who don't change plans will see monthly premiums rise by $50 or more in all 50 states, more than $75 in 37 states and more than $100 in four states, while the AARP Medicare Rx Saver plan will rise by $50 or more in 33 states. Together the two plans have more than 2 million members, and 15 drugs including Ozempic, Rybelsus and Wegovy will get Medicare-negotiated prices starting Jan. 1.
Related markets
Latest news
- Earnings live updates: All eyes on Musk and Meta as Q3 earnings rev up
Big tech is the focus of this week's earnings season, with Meta (META), SpaceX (SPCX) and Tesla (TSLA) due to report. SpaceX and Netflix (NFLX) kick off on Tuesday after the bell, while Tesla and Meta report on Wednesday, offering an early read on the Magnificent Seven and the AI trade. Wall Street estimates S&P 500 earnings growth of 29.6%, according to FactSet; if that holds, it would be the third straight quarter of growth above 25%. General Motors (GM), IBM (IBM), United Airlines (UAL) and Procter & Gamble (PG) also report this week.
- Mysterious UAV Enters Lithuania as NATO Fighters Fail to Intercept It
On the morning of October 18, an unidentified drone entered Lithuanian airspace between 6:00 and 8:00, prompting an air alert and the scrambling of NATO jets, which escorted the object but could not shoot it down due to difficult weather. Debris later found in Juojonis village in Pasvalys district was initially identified as drone parts, and the military says it may have entered from Poland. Latvia issued a similar warning for several regions and cancelled it at 8:12, though its army has not confirmed the object was a drone. Prime Minister Mindaugas Sinkevičius said the sabotage hypothesis must be verified, while law enforcement works to determine the drone's origin; earlier, on September 15, Italian Eurofighter Typhoons shot down a drone that had flown into Lithuania from Belarus.
- Corning Is Moving Beyond Fiber Cables. Can AI Networking Pay Off?
Corning (GLW) is extending beyond fiber cables into optical components inside AI systems, having demonstrated optical connectivity with Lumentum and Astera Labs on October 12 and partnered with Nvidia on a planned tenfold expansion of optical connectivity capacity in the US. Its Optical Communications sales rose 32% year-over-year to $2.07 billion in Q2 2026, and management sees a potential $10 billion revenue opportunity by 2030 from a photonics platform, though timing and adoption remain uncertain. Still, the valuation is elevated, with a forward non-GAAP P/E of 44.81x, about 84% above its 5-year average of 24.31x, while analysts expect EPS to grow 30.41% in December 2026 and 33.02% in December 2027. The article notes that slower AI spending or delayed CPO adoption could pressure the stock.
- Google’s Next AI Chip Is Running Late. Why Marvell May Be Fine
GF Securities says one part of Google's TPU v9 design slipped about three weeks, likely due to a redesign, pushing the timeline back roughly a quarter, with mass production now expected in Q2 2027. Packaging substrate yields of just 45% to 50% are a key obstacle, but GF sees no demand problem, citing strong TPU demand from Google and external customers such as Anthropic. The firm points to MediaTek, not Marvell (MRVL), as facing short-term headwinds, so any benefit to Marvell appears indirect. At 63x forward earnings, a 66% premium to its five-year average P/E of 38.02x, the article concludes the delay is not by itself a reason to buy.
- Stocks bounce back, Anthropic's "Public Benefits", and Musk's promise to American kids
The 8:30 show, hosted by Julie Hyman, Pras Subramanian and Jake Conley, discusses the stock market's rebound. Other topics include Anthropic's (ANTH.PVT) commitment to a “Public Benefit” fund, Elon Musk's promise to American children about SpaceX (SPCX) stock ahead of earnings, and doubts over an IPO after Microsoft (MSFT) withdrew.
- Microsoft vs. Alphabet: Is GOOGL’s Cloud Growth Worth More Than Investors Think?
Microsoft (MSFT) and Alphabet (GOOGL) trade at forward P/E ratios of 25.13 and 22.83, respectively. Google Cloud revenue jumped 82% to $24.8 billion in the second quarter, with operating income rising from $2.8 billion to $8.8 billion, while Azure and other cloud services grew 43%. Both companies face heavy infrastructure spending: Microsoft spent $35.8 billion on property and equipment, pushing its cloud gross margin down to 65%, while Alphabet spent $44.9 billion, leaving roughly negative $5.85 billion in quarterly free cash flow. The article argues Alphabet's $9.11 EPS is unreliable because about $98 billion came from net other income, so its 30% operating-income growth better reflects underlying performance. Microsoft has a more diversified earnings base and higher consolidated operating margins, but the key question is whether either company can turn AI demand into cash after paying for infrastructure.
Get the briefing on Telegram or Zalo
Join the Upside Telegram channel or Zalo group for the Vietnam stocks and gold briefing at 8:00 and 19:00 (Vietnam time) on trading days, plus a weekly wrap on Saturday morning.